Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 9, 1997

View Archived Issues

Company Profile: Elan

Novo Nordisk develops A1 agonist with neuroprotectant activity

Efficacy of TxA2 antagonist in IBD established

New muscarinic compound from Wyeth-Ayerst

TheraTech: Q3 1997 highlights

ImClone Systems: Q3 1997 highlights

Pfizer improves on NMDA antagonists

Promising results reported from pilot trial of Repel

Enzon: Q1 1998 highlights

New antihyperalgesic agents from Adolor

NPS and SmithKline Beecham sign additional extension of osteoporosis agreement

Novel valproic acid prodrug reported at scientific meeting

Preclinical profile of Novartis' dermatology candidate

AMPA antagonist investigated for treatment of drug withdrawal

Safe and effective new D2 partial agonist in development at Wyeth-Ayerst

Alteon prepares new AGE inhibitors

CRF antagonists from DuPont Merck for anxiety, depression and related disorders

Lilly discovers highly potent and selective NPY Y1 receptor antagonists

Adefovir dipivoxil now available in expanded access program

Seragen submits BLA for CTCL biological product

Novel liver-targeted conjugate for hepatitis B virus infection

Preclinical toxicity profile of ISIS-2503

BioTime reports preliminary phase III data from Hextend trial

FDA approves shorter treatment claim for Mentax

Boehringer Mannheim returns to PDL rights to two antiviral compounds

StressGen prepares to evaluate Oncocine in clinical trials

FDA advisory committee recommends approval of TOBI

Propecia recommended for approval for hair loss in men

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...